Chest
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe COPD experience marked deterioration in lung function and breathlessness compared to patients with mild-to-moderate COPD. We report improvement of dyspnea and lung function in patients with severe COPD in the BLAZE study with QVA149, a dual bronchodilator combining the long-acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), versus placebo and tiotropium. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, AstraZeneca, Forest Laboratories, Pfizer, Schering Plough, Grant monies (from industry related sources): GSK, Schering Plough, Methapharma, AstraZeneca, Merck Canada, Forest Laboratories, Novartis Donald Mahler: Grant monies (from industry related sources): Boehringer Ingelheim, Novartis, and Sunovion, Consultant fee, speaker bureau, advisory committee, etc.: GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion Tracy White: Employee: Novartis Pharmaceuticals Corporation Vijay Alagappan: Employee: Novartis Pharmaceuticals Corporation Hungta Chen: Employee: Novartis Pharmaceuticals Corporation Karoly Kulich: Employee: Novartis Pharma AG Nicola Gallagher: Employee: Novartis Horsham Research Centre Donald Banerji: Employee: Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Heinrich WorthClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
AsthmaSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: Asthma is a heterogenous disease with distinct clinical phenotypes, including the exacerbation-prone phenotype. This subset of patients contributes to disproportionately high morbidity, mortality and healthcare utilization among all asthma patients. We aimed to investigate the factors that are associated with frequent asthma exacerbations in patients with severe asthma. ⋯ The following authors have nothing to disclose: Jessica Tan, Mariko Koh, Anthony Yii, Adrian ChanNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) is being developed for treatment of COPD. This study assessed the efficacy and safety of two twice-daily (BID) FDCs vs monotherapies and placebo. ⋯ Dave Singh: Grant monies (from industry related sources): AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingleheim, Roche, Novartis, Cipla, Almirall and Merck, Consultant fee, speaker bureau, advisory committee, etc.: AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingleheim, Roche, Novartis, Cipla, Almirall and Merck Paul Jones: Consultant fee, speaker bureau, advisory committee, etc.: Almirall S.A., Consultant fee, speaker bureau, advisory committee, etc.: Forest Laboratories, Inc. Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Almirall S.A., Consultant fee, speaker bureau, advisory committee, etc.: Forest Laboratories, Inc., Grant monies (from industry related sources): E D Bateman's has received payment from Almirall for participation in clinical trials Stephanie Korn: Consultant fee, speaker bureau, advisory committee, etc.: Almirall Cristina Serra: Employee: Almirall S.A. Eduard Molins: Employee: Almirall S.A. Cynthia Caracta: Employee: Almirall S.A. Esther Garcia Gil: Employee: Almirall S.A. Anne Leselbaum: Employee: Almirall S.A.This abstracts presents the results of a double blind, randomized Phase III trial of a fixed combination of two products, each of which are approved as monotherapies for the treatment of COPD.
-
TransplantationSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: Cor pulmonale can complicate end-stage lung disease in chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis (CF). Although the prevalence of pulmonary hypertension (PH) has been described in CF patients, these studies often drew small sample sizes from single centers. We aimed to describe the independent association between CF and PH compared to COPD and IPF. ⋯ The following authors have nothing to disclose: Nona Mei, Alex BalekianNo Product/Research Disclosure Information.
-
Pediatric Pulmonary Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Extremly low birth weight (ELBW) is one of the main reason for neonatal intensive care. ELBW infants are at risc for developing respiratory distress syndrome (RDS), hypothermia, intraventricular hemorrhage and symptomatic persistant ductus arteriosus. Improper care at birth may worsen the symptomatology and the outcome of these prematures. ⋯ High frequency oscillatory ventilation should be the elective ventialtion mode in ELBW infants with RDS and/or pulmonary hemorrhage in order to get prompt respons and reduce major complicationsReference #1: Knobel R, Diane Holditch-Davis. Thermoregulation and Heat Loss Prevention After Birth and During Neonatal Intensive-Care Unit Stabilization of Extremely Low-Birthweight Infants. JOGNN May/June 2007. 36(3): 280-287.DOI: 10.1111/j.1552-6909.2007.00149.xReference #2: Cloherty, J., Eichenwald, E, Hansen AR, Stark, A.R, (Eds.). (2012). Manual of neonatal care (7th ed.). Philadelphia: Lippincott-Williams & Wilkins.Reference #3: AlKharfy T M. High-Frequency Ventilation in the Management of Very-Low-Birth-Weight Infants with Pulmonary Hemorrhage. Amer J Perinatol 2004; 21(1): 19-26. DOI: 10.1055/s-2004-820505DISCLOSURE: The following authors have nothing to disclose: Marta Simon, Manuela Cucerea, Zsuzsanna Gall, Monika Rusneac, Luminita Zahiu, Carmen Movileanu, Raluca Marian, Laura SuciuNo Product/Research Disclosure Information.